ANY (PATHOGEN - PATIENT - TIME)
SeeQ Diagnostics
Faster diagnostics for better patient outcomes
TECHNOLOGY
Bringing Rapid Metagenomics to Patients
Unique Chemistry
Applying a decade of experience in developing molecular biology tools for microbial sample preparation, the SeeQ team has developed novel chemistry to enrich for the microbial DNA signal in human blood
State-of-the-art Integration
Collaboration with world leading liquid handling robotic partners combined with state-of-the-art rapid on-site sequencing
will enable us to deliver a pathogen ID in 6-8 hours
Novel Classification Software
The bioinformatic team at SeeQ delivers fully integrated, rapid and reliable software from DNA sequence to pathogen identification, using novel features to enhance assay accuracy
SeeQ Diagnostics' technology is based on know-how developed in Professor Mads Albertsen's group at Aalborg University in Denmark during rapid viral variant tracking for SARS-CoV-2. This was converted into a concept, "SepSeeQ", generally applicable for any pathogen and applied in a prospective observational clinical study (n=40) at Aalborg University Hospital emergency ward. Here SepSeeQ had 100% sensitivity compared to gold-standard blood culture with MALDI-TOF pathogen identification (n=11), and further identified a relevant pathogen in an additional 11 patients.
SepSeeQ development has been supported by the Independent Research Fund Denmark (0.65 mio EUR) and Innovation Fund Denmark (0.2 mio EUR). The SeeQ project was launched with a 3 mio EUR grant from the BioInnovation Institute accelerator 1st April 2025.
From the academic lab to clinical application
OUR TEAM
Anders B. Sørensen, PhD-MBA
CEO/CPO (EiR BII), Co-founder
Morten Eneberg Nielsen, PhD
Head of R&D, Co-founder
Mads Albertsen, PhD
Advisor (PI BII), Co-founder
Christian B. Thygesen, PhD
Head of BD and Software Development, Co-founder
Hans L. Nielsen, MD, PhD
Clinical Advisor
Anne Mette F. Eskildsen, Msc
Research Assistant
NEWS
SeeQ Publishes first clinical data on SepSeeq
March 2025
In collaboration with the founding academic group SeeQ publishes clinical data from the first retrospective clinical study applying SepSeeQ in an emergency ward setting
SeeQ Receives 3 mio EUR in funding for BioInnovation Institute
April 2025
SeeQ enters the BioStudio accelerator program at BioInnovation Institute with 3 mio EUR in funding for the next 3 years to
establish product development and commercialization teams
Contact
SeeQ Diagnostics
BioInnovation Institute
Ole Maaløes Vej 3
2200 København
Denmark
Info@seeqdx.com